Visiongain Publishes Next-Generation Sequencing Market Report 2020-2030

29 July 2020

Visiongain has launched a new report Next Generation Sequencing Market Forecast 2020-2030: Forecasts by Next Generation Sequencing (NGS) Market by Product (Consumables, Platforms, and Services) Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research, and Others), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing, and Other Technologies), and End-user (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, and Others) and by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies.

Next-generation sequencing (NGS) is a high-throughput sequencing which allows for sequencing of millions and billions of DNA and RNA strands much more quickly and cheaply which has revolutionised the study of genomics and molecular biology. The all-in-one methodology obtainable by next generation sequencing curtails the time required to detect the cause of a condition, and compared to sequential molecular tests, thereby contributing to the improved health outcome. In the current scenario, liquid biopsies for early detection and monitoring of cancer, and diversification of the reproductive health market exhibits a large number of possibilities for the technology in the near future. NGS is used to execute various applications such as biomarker discovery, oncology studies, personalized medicine, agricultural & animal research, and others. NGS has streamlined nucleotide analysis and has broadly substituted conventional tools of genomics, especially microarray efficiently. Hence, these aforementioned factors have led to the increasing popularity of next generation sequencing driving the market growth.

Sequencing by synthesis (SBS), is one of the most prominent and greatly adopted next-generation sequencing (NGS) technologies used by researchers and scientist worldwide. In 2019, the SBS segment is estimated to be the dominant technology in the NGS market. The leading market position of this segment is mainly due to the development of new and advanced NGS platforms and the growing demand for Illumina’s systems, as it is the major provider of NGS platforms that use the SBS technology. Also, this technology offers a massive sequence throughput at modest costs, even in a single sequencing run.

The Visiongain report analyst commented “that with the reducing cost of sequencing, Next Generation Sequencing (NGS) is expected to witness diversification into a large number of clinical areas. Currently, next generation sequencing is accredited as the primary technology accountable for the burgeoning field of oncology, Mendelian diseases, and complex disease testing.”

Moreover, Next-generation sequencing has begun to transform prenatal diagnosis and prenatal Whole Exome Sequencing (WES) has become a reality. WES has enhanced genetic diagnosis by 16% to 45% in paediatric and adult populations. WES has also led to improvisation in detection of a genetic aetiology for prenatally diagnosed fatal structural abnormalities. Prenatal WES is usually performed as trio sequencing of fatal, maternal and paternal DNA to facilitate more rapid results. WGS could be helpful in understanding the alterations in the genetic sequence of the COVID-19 viral genomes collected from different patients thereby allowing researchers to build a viral ‘family tree’ and contribute to efforts to monitor disease spread within and between populations over time. The UK government has launched a new alliance to sequence the genomes of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. Funded by a £20 million investment, the COVID-19 Genomics UK Consortium (COG-UK) is comprised of the NHS, Public Health Agencies, the Wellcome Sanger Institute and several academic institutions. This could open several new opportunities to the manufacturers around the globe thereby driving the market growth during the forecast period. However, accuracy & standardization concerns and ethical & legal limitations associated with NGS restrain the market growth.

The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., Beijing Genomics Institute, Qiagen N.V., 454 Life Sciences Corporation (Roche Holding AG), Agilent Technologies, Inc., Perkinelmer, Inc., Genomatix GmbH, and PierianDx.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021


Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021


Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021


Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021